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Abstract
Aims/hypothesis Gestational diabetesmellitus (GDM) is asso-
ciated with an increased future risk of obesity in the offspring.
Increased adiposity has been observed in the newborns of
women with GDM. Our aim was to examine early fetal adi-
posity in women with GDM.
Methods Obstetric and sonographic data was collated for 153
women with GDM and 178 controls from a single centre in
Chennai, India. Fetal head circumference (HC), abdominal
circumference (AC), femur length (FL) and biparietal diame-
ter (BPD) were recorded at 11, 20 and 32 weeks. Anterior
abdominal wall thickness (AAWT) as a marker of abdominal
adiposity at 20 and 32 weeks was compared between groups.
Adjustments were made for maternal age, BMI, parity, gesta-
tional weight gain, fetal sex and gestational age.
Results Fetuses of women with GDM had significantly higher
AAWT at 20 weeks (β 0.26 [95% CI 0.15, 0.37] mm,
p< 0.0001) despite lower measures of HC, FL, BPD and
AC. AAWT remained higher in the fetuses of women with
GDM at 32 weeks (β 0.48 [0.30, 0.65] mm, p< 0.0001)
despite similar measures for HC, FL, BPD and AC between
groups. Both groups had similar birthweights at term. There
was an independent relationship between fasting plasma glu-
cose levels and AAWT after adjustment as described above.
Conclusions/interpretation A ‘thin but fat’ phenotype signi-
fying a disproportionate increase in adiposity despite smaller
or similar lean body mass was observed in the fetuses of
mothers with GDM, even at 20 weeks, thus pre-dating the
biochemical diagnosis of GDM. Increased AAWT may serve
as an early marker of GDM.
Keywords Abdominal fat . Fetal adiposity . Gestational
diabetes . Intrauterine programming . Offspringmetabolic
risk . Prediction
Abbreviations
1hPG 1 h plasma glucose
2hPG 2 h plasma glucose




FPG Fasting plasma glucose
GDM Gestational diabetes mellitus
GWG Gestational weight gain
HC Head circumference
LGA Large for gestational age
SGA Small for gestational age
Introduction
Gestational diabetes mellitus (GDM) is associated with sever-
al maternal and neonatal complications [1]. Increased fetal
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-016-4166-2) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
* Ponnusamy Saravanan
p.saravanan@warwick.ac.uk
1 Populations, Evidence and Technologies, Division of Health
Sciences, Warwick Medical School, University of Warwick, Gibbet
Hill, Coventry CV4 7AL, UK
2 Seethapathy Clinic and Hospital, Chennai, India
3 Mediscan Systems, Mylapore, Chennai, India




size, defined as macrosomia or large for gestational age
(LGA), is an important early fetal complication, which has
been shown to be reduced by up to 50% with intervention
[2, 3]. In the long term, the offspring of mothers with GDM
have a two- to fourfold higher future risk of obesity and dia-
betes [4–6], with evidence for increased BMI, body fat and
subcutaneous abdominal fat in early childhood and adoles-
cence [7–9].
There is emerging evidence that this increase in adiposity
in the offspring of women with GDM begins in early fetal life
[10, 11]. Such fetuses exhibit a ‘thin–fat’ phenotype i.e. have
preferential growth of insulin sensitive adipose tissue mass
over that of fat-free lean tissues [10], with a higher total
fat:lean mass ratio [12]. However, current evidence for a link
between increased fetal adiposity andGDM is restricted to late
pregnancy [11–14] and birth [10, 15, 16] (electronic supple-
mentary material [ESM] Table 1).
Recently, Sovio et al reported early growth differences in
the fetuses of women with GDM and controls in a prospective
cohort of nulliparous women in the UK [17]. Using abdominal
circumference (AC) as a surrogate for fetal adiposity, they
observed increased fetal AC for women with GDM even at
the time of diagnosis (at 28 weeks), although no difference
was observed between groups at 20 weeks. In addition, the
AC growth velocity at 20–28 weeks was significantly higher
in the fetuses of mothers who later developed GDM.
Traditionally, GDM is diagnosed at around 28 weeks of ges-
tation by an OGTT [18]. Such evidence for early abnormal
fetal growth pre-dating the routine biochemical diagnosis of
GDM, calls for an earlier diagnosis and intervention strategy
for GDM.
Anterior abdominal wall thickness (AAWT) has been used
previously as a reliable marker of fetal abdominal adiposity
[10, 14, 19]. Our aim was to assess fetal body size and ab-
dominal adiposity in GDM during early pregnancy, prior to
the biochemical diagnosis of GDM.
Methods
A retrospective analysis of maternal demographic, anthropo-
metric and fetal sonographic data was conducted for all wom-
en attending the Seethapathy Clinic & Hospital, Chennai,
India, for routine antenatal care from September 2011 to
December 2013. Patient consent and investigations were car-
ried out in accordance with the revised Declaration of Helsinki
(2008) (www.wma.net/en/30publications/10policies/b3
/index.html).
A total of 153 consecutive women diagnosed as having
GDM at the time of an OGTT (24–28 weeks) were identified.
For each patient, at least one age- and parity-matched woman
without GDM who was cared for during the same period and
delivered in the same hospital was selected as a control.
Women with, pre-existing diabetes, multiple pregnancy or fe-
tal anomalies were excluded.
Ultrasound scans were performed at two centres, Mediscan
and Seethapathy Hospital, by two independent sonographers
using standardised techniques. All patients underwent a dating
scan at 10–12weeks and a fetal anomaly scan at 19–21weeks.
Women with GDM underwent fetal growth scans at 28, 32
and (if clinically indicated) 36 weeks of gestation. All control
pregnant women had a scan at around 32 weeks, according to
routine clinical practice in the region. Head circumference
(HC), AC, femur length (FL) and biparietal diameter (BPD)
were measured at each time point. AAWTwas measured from
archived images using SonoCare Medialogic Solutions soft-
ware (version 6.8) by the two sonographers, who were blinded
to disease status. AAWT measurements were obtained at 20
and 32 weeks using standardised techniques, as described pre-
viously [19] and used as measures of fetal adiposity. In brief,
the standard plane used to measure the AC was utilised to
calculate the AAWT. The AAWTwas calculated as the thick-
ness of the echogenic rimmeasured at a point 2–3 cm lateral to
the umbilical cord insertion into the portion of the abdominal
wall closer to the probe, taking care not to include the
hypoechoic area between the abdominal wall and the liver
(shown in Fig. 1).
Routinely recorded neonatal anthropometry consisting of
HC, length and birthweight was retrieved. LGA was defined
as birthweight >90th centile for gestational age, and small for
gestational age (SGA) as birthweight <10th centile for gesta-
tional age, for gestational age ranging between 28 and
41 weeks. Birthweight centiles were calculated using the
WHO weight percentiles calculator with a mean birthweight
of 3230 g (SD 427.3 g) [20–24].
Gestational weight gain (GWG) was defined as the total
weight gain between the first booking visit and delivery. The
rate of GWGwas calculated as the GWG divided by the num-
ber of weeks between booking and delivery. Since gestational
age at booking was variable between participants, the rate of
GWG was used instead of GWG as a covariate in regression
models. Multiparity was defined as more than one live or still-
birth after 24 weeks’ gestation.
Diagnosis of GDMUniversal screening was used to diagnose
GDM. All women underwent a fasting plasma glucose (FPG)
test at booking. Those with FPG levels ≥7.0 mmol/l (126 mg/
dl) were considered to have pre-gestational diabetes. Women
with FPG levels of 5.1–6.9 mmol/l (92–125 mg/dl) at booking
were considered to have GDM after confirmation by a second
FPG test. For all other women, a 75 g OGTTwas carried out at
between 24 and 28 weeks. Only women who underwent an
OGTT were included in this analysis. GDM was diagnosed
based on the International Association of the Diabetes and
Pregnancy Study Groups criteria i.e. a FPG level of
≥5.1 mmol/l (92 mg/dl), a 1 h plasma glucose (1hPG) level
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of ≥10.0 mmol/l (180 mg/dl) or a 2 h plasma glucose (2hPG)
level of ≥8.5 mmol/l (153 mg/dl). A FPG level of <5.6 mmol/l
(100 mg/dl) and a 1hPG level of <7.8 mmol/l (140 mg/dl)
were considered the optimum glycaemic targets in pregnancy.
Diet and lifestyle advice was given first to all women with
GDM, followed by insulin if glycaemic targets were not met.
Statistical analysis The Student’s t test and χ2 test were used
to compare means and proportions between the GDM and
control groups. Multivariable linear regression was used to
analyse differences in fetal biometric variables after adjust-
ment for maternal age, BMI, parity, GWG, fetal sex and ges-
tational age at scan. IBM SPSS Statistics software (version
22.0, Chicago, IL, USA) was used for all analyses.
Results
A total of 178 controls and 153 women with GDM who had
complete sonographic data were included in the analysis. Fetal
biometry was compared between the GDM and control groups
at 12, 20 and 32 weeks of gestation. Complete fetal biometric
data was available for 325 women at the 20 week scan (mean
±SD, 20.9±1.1 weeks) and for 316 women at the 32 week
scan (mean±SD, 32.5±1.6 weeks). Archived images were
unavailable for measuring AAWT for three women at the
20 week scan. Baseline characteristics of the two groups are
shown in Table 1. While maternal age, BMI, height and parity
were comparable between the two groups, women with GDM
had significantly less GWG than controls. At birth, neonatal
weight, HC and length, as well as the proportion of LGA and
SGA neonates, were similar in the two groups.
At the 12week scan, both groups had similar fetal variables
(GDM vs control group (mm): HC, 66.2±28.7 vs 65.5±29.6;
AC, 52.3 ± 25.1 vs 51.7 ± 22.9; FL, 7.5 ± 7.3 vs 7.5 ± 7.5;
BPD, 18.5±7.9 vs 19.2±9.9; p>0.05 for all comparisons)
Differences in fetal biometry at 20 weeks of gestation The
mean gestation at the 20 week scan was 20.9 ± 1.1 weeks
(GDM vs control group: 21.06 ± 1.23 vs 20.82 ± 0.96,
p=0.062). Table 2 shows the differences in fetal biometry
and AAWT between the GDM and control groups. Fetuses
of women who were later diagnosed with GDM had a signif-
icantly higher AAWT but smaller measures for HC, AC, FL
and BPD. These differences in traditional biometric measures
and AAWT between the two groups persisted even after
adjusting for maternal age, BMI, parity, GWG, fetal sex and
gestational age at scan.
Differences in fetal biometry at 32 weeks of gestation The
mean gestation at the 32 week scan was 32.5 ± 1.6 weeks
(GDM vs control group: 32.13 ± 1.47 vs 32.93 ± 1.47,
p<0.0001). At 32 weeks, fetuses in the GDM group had a
higher AAWT after adjustment for possible confounders, as
described above (Table 2). HC and FL remained lower in the
GDM group after adjustment for maternal age, BMI, parity,
fetal sex and gestational age at scan. The differences in HC
and FL were lost when GWG was included in the model.
Sex-specific changes of AAWT Upon performing the analy-
sis separately in male and female fetuses, the difference in
AAWT between GDM and controls persisted for both sexes
after adjustment for maternal age, BMI, parity, GWG and
gestational age at 20 weeks (β coefficient 0.287 [95% CI
0.124, 0.450], p= 0.001 for female fetuses; β coefficient
0.220 [95% CI 0.061, 0.381], p=0.007 for male fetuses) and
32 weeks (β coefficient 0.347 [95%CI 0.083, 0.610], p=0.01
for female fetuses; β coefficient 0.639 [95% CI 0.406, 0.871],
p<0.0001 for male fetuses).
AAWT and glycaemia at OGTT The mean gestation at
OGTT was 24.7 ± 2.45 weeks (GDM vs control group:
27.31±3.10 vs 25.87±3.08, p<0.0001). There was an inde-














bFig. 1 (a, b) AAWT
measurements for (a) control and
(b) GDM fetuses at 20 weeks of
gestation. Yellow dashed lines 1
and 2 indicate the AC
measurements. The space
between the two bold X symbols
at the edge of the abdominal wall
indicates the AAWT
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At 20 and 32 weeks, the FPG level at OGTTwas significantly
associated with AAWT after adjustment for maternal age,
BMI, parity, GWG, fetal sex and gestational age at scan
(20 weeks: β coefficient 0.195 [95% CI 0.120, 0.270],
p<0.0001; 32 weeks: β coefficient 0.233 [95% CI 0.111,
0.355], p<0.0001). Neither 1hPG nor 2hPG levels were in-
dependently related to fetal abdominal adiposity.
Discussion
Our results provide novel evidence that higher fetal adiposity is
associated with GDM from as early as 20 weeks of gestation, a
mean of 4.7 weeks before the biochemical diagnosis of GDM, in
a South Asian population. The higher fetal adiposity at 20 weeks
persisted after adjustment for maternal age, BMI, parity, GWG,
fetal sex and gestational age at scan. The current literature on
fetal adiposity in GDM reports a higher AAWTonly in the third
trimester, that is, well after 26 weeks of gestation and after the
diagnosis of GDM [10–16]. To our knowledge, this is the first
report of adiposity in early fetal life at 20 weeks. The increase in
AAWT observed at 20 weeks persisted even at 32 weeks of
gestation despite treatment for GDM.
An important point to note is that the excess adiposity was
observed despite a smaller lean fetal mass (smaller AC, HC,
FL and BPD at 20 weeks), signifying a disproportionate in-
crease in adipose tissue over lean body mass. The dispropor-
tion between lean fetal mass and adiposity persisted at
32 weeks, with fetuses in the GDM group having a similar
AC, HC, FL and BPD but higher AAWT.
In line with previous reports, women with GDM had sig-
nificantly less GWG than controls [25]. After addition of
GWG to the model, the differences in measures of lean fetal
mass between GDM and controls at 32 weeks were lost, but
differences in fetal adiposity persisted. These findings high-
light the differential effects of GWG on fetal growth of lean
and adipose tissue. With progressing gestation from 20 to
32 weeks, the difference in adiposity between GDM and con-
trols increased, but the difference in measures of lean fetal
mass became insignificant (Table 2), indicating the preferential
growth of adipose tissue in the fetuses of women with GDM.
At birth, fetuses did not differ between groups with respect
to birthweight or the proportion of LGA or SGA, again
emphasising that increased fetal adiposity was observed in
GDM despite a similar overall size. Most other studies that
reported increased fetal adiposity in GDM also reported a
Table 1 Baseline maternal and
birth characteristics in the GDM
and control groups
Characteristic GDM group Control group p value
Maternal
Age 28.5 ± 3.8 28.8 ± 4.2 0.610
BMI, kg/cm2 25.9 ± 5.8 23.7 ± 6.6 0.002
Height, cm 155.2 ± 19.1 150.8 ± 33.40 0.142
Weight, kg 65.9 ± 12.5 60.6 ± 16.0 0.001
Multiparity 7/145 (4.8) 3/175 (1.7) 0.123
Previous GDM 6/153 (3.9) 0/178 (0) 0.008
Family history of diabetes 75/153 (49.0) 59/178 (33.1) 0.003
FPG, mmol/l 5.3 ± 0.7 4.4 ± 0.5 <0.0001
1hPG, mmol/l 9.7 ± 1.9 7.0 ± 1.5 <0.0001
2hPG, mmol/l 8.1 ± 1.8 5.9 ± 1.2 <0.0001
GWG, kg 8.62± 4.34 10.73 ± 4.48 <0.0001
GWG/week, kg 0.34± 0.20 0.41 ± 0.17 0.001
Birth
Male sex 69/153 (45.1) 98/178 (55.1) 0.071
Birthweight, g 3020± 464 3110± 383 0.070
Gestational age at birth, weeks 38.5 ± 1.5 38.8 ± 1.1 0.056
Caesarean section 83/153 (54.2) 75/178 (42.1) 0.028
Elective Caesarean section 26/83 (31.3) 27/75 (36.0) 0.534
HC, cm 33.75 ± 1.86 33.74 ± 1.36 1.00
Length, cm 47.79 ± 2.70 47.64 ± 2.14 0.61
LGA 35/153 (22.9) 42/178 (23.6) 0.877
SGA 21/153 (13.7) 15/178 (8.4) 0.123
Data are means ± SD or n (%)
p value refers to the Student’s t test for linear variables and the χ2 test for percentages
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higher offspring birthweight (ESMTable 1) [10, 12–14, 16]. It
could therefore be argued that increased fetal adiposity ob-
served in these studies was in fact a consequence of an overall
increased size in GDM. Our results of increased fetal adiposity
but similar fetal and neonatal size signify a preferential in-
crease in adiposity over the growth of lean body mass in
GDM. Catalano et al reported a similar disproportionate in-
crease in fat mass compared with fat-free mass at birth in
neonates of mothers with GDM [10]. Our study extends this
finding to early fetal life at 20 weeks.
It is possible that the disproportionate fetal growth of adipose
tissue over lean body mass is a prominent feature of glucose
intolerance in South Asians. South Asian neonates are known
to have a relatively high body fat and low lean mass for a given
body weight hence the name ‘thin–fat’ babies [26].We postulate
that this differential growth process starts in early fetal life and is
aggravated by GDM. The presence of other non-glycaemic fac-
tors such as dyslipidaemia, which is known to be higher in South
Asians [27] and in GDM [28], could also contribute to higher
fetal adiposity in GDM in South Asians [29].
We also observed that fetal adipositywas closely related to the
maternal FPG level at OGTT at 24.7 weeks. This relationship
betweenmaternal FPG and adiposity has been reported at 28 and
37 weeks in women with normal glucose tolerance [30].
Catalano et al reported an independent relationship between ma-
ternal FPG level at OGTT and adiposity at birth in neonates of
mothers with GDM [10]. Our study extends this association to
early fetal adiposity at 20 weeks, prior to the diagnosis of GDM.
Our study had important limitations. It was retrospective
and restricted to an urban, middle class southern Indian pop-
ulation. Detailed information on treatment of GDM and
glycaemic control, which affects late pregnancy fetal growth,
was not available. While treatment of GDMmight have influ-
enced the results of the 32 weeks, it would not affect our
findings at 20 weeks. However, glucose measurement at the
time of the 20 week scan would have provided more insight
into the relationship between AAWTand maternal FPG level.
A detailed dietary history, such as vegetarianism and total
daily protein intake, which could in turn affect fetal growth,
was not available. However, since this was a homogeneous
cohort of affluent urban women from a single centre, the dif-
ferences between groups are assumed to be small.
The key strength of our study is the availability of AAWT
data at 20 weeks. AAWT can be measured easily from the
Table 2 Fetal biometric variables







At 20 weeks’ gestation (prior to GDM diagnosis)
HC, mm 178.12 ± 11.59 181.39 ± 11.21 −4.19 (−6.12, −2.26) <0.0001
−4.43 (−6.63, −2.23)a <0.0001a
AC, mm 154.41 ± 11.53 156.57 ± 11.12 −2.99 (−5.03, −1.16) 0.004
−2.63 (−4.92, −0.34)a 0.025a
FL, mm 34.29± 4.32 34.86 ± 2.77 −1.13 (−1.61, −0.65) <0.0001
−1.13 (−1.67, −0.58)a <0.0001a
BPD, mm 48.92± 3.12 49.95 ± 3.31 −1.20 (−1.78, −0.62) <0.0001
−1.29 (−1.91, −0.63)a <0.0001a
AAWT, mm 2.63± 0.51 2.39± 0.41 0.28 (0.17, 0.38) <0.0001
0.26 (0.15, 0.37)a <0.0001a
At 28–32 weeks’ gestation
HC, mm 288.23 ± 17.71 297.81 ± 14.15 −2.62 (−5.19, −0.06) 0.040
−2.51 (−5.41, 0.38)a 0.089a
AC, mm 265.87 ± 22.04 276.78 ± 19.02 −2.82 (−6.21, 0.57) 0.100
−2.09 (−5.86, 1.68)a 0.276a
FL, mm 60.14± 4.80 62.79 ± 3.85 −0.87 (−1.57, −0.16) 0.017
−0.55 (−1.27, 0.17)a 0.131a
BPD, mm 80.73± 5.23 83.29 ± 4.42 −0.35 (−1.12, 0.42) 0.37
−0.20 (−1.04, 0.65)a 0.65a
AAWT, mm 4.65± 0.81 4.37± 0.66 0.50 (0.34, 0.66) <0.0001
0.48 (0.30, 0.65)a <0.0001a
The control group was used as the reference category
β coefficient for respective fetal biometry variables using multivariable linear regression after adjustment for
maternal age, BMI, parity, fetal sex and gestational age
a Adjustment as above plus GWG/week
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routine 20 week anomaly scan carried out as a standard pro-
cedure across the world. The AAWT calculation uses data
from the plane that is routinely captured for calculating AC.
Thus, AAWTcould serve as a potential marker to stratify risk
and allow early biochemical testing for GDM in the subgroup
of women with increased fetal adiposity. However, the poten-
tial of fetal adiposity measures for diagnosis and risk stratifi-
cation needs to be studied in larger, prospective studies.
In summary, our study extends previous observations of
fetal and neonatal adiposity in GDM to early fetal life at
20 weeks, pre-dating the biochemical diagnosis of GDM,
and to a high-risk South Asian ethnic minority group. Our
evidence highlights a need for more research into early fetal
composition and adiposity in GDM, in larger prospective
studies and other ethnic populations.
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